Management of Osteoporosis in CKD

Area of Science:

• Nephrology
• Endocrinology
• Orthopedics

Background:

• CKD mineral and bone disease (CKD-MBD) is highly prevalent in patients with moderate to severe chronic kidney disease (CKD).
• Traditionally, managing CKD-MBD has focused on biochemical parameters, with limited strategies for skeletal fragility.
• Recent advancements offer new approaches to assess and manage bone health in CKD.

Purpose of the Study:

• To review the impact of Kidney Disease: Improving Global Outcomes (KDIGO) guidelines on CKD-MBD management.
• To discuss the efficacy and safety of antiosteoporosis pharmacologic agents in CKD patients.
• To explore novel antiosteoporosis therapies and their potential challenges in the context of CKD.

Main Methods:

• Review of recent prospective studies on bone mineral density (BMD) and fracture prediction in CKD.
• Analysis of literature on the use of established osteoporosis pharmacologic agents in CKD populations.
• Examination of emerging antiosteoporosis agents and their applicability to CKD patients.

Main Results:

• Dual-energy x-ray absorptiometry (DXA) for BMD measurement effectively predicts fractures in CKD, enabling risk stratification.
• Pharmacologic agents commonly used for osteoporosis in the general population appear safe and effective for CKD patients.
• Novel agents show promise but require further investigation regarding safety and efficacy in CKD.

Conclusions:

• BMD assessment via DXA is a valuable tool for identifying fracture risk in CKD.
• Existing osteoporosis treatments can be safely adapted for CKD patients, guided by updated KDIGO recommendations.
• Further research is needed to optimize the use of novel antiosteoporosis agents in CKD management.